// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Pooled data from 3 randomized phase 3 studies: 11q deletion (del11q) is not a prognostic factor for adverse outcomes for patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with ibrutinib (Ibr)

A Janssens - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bendamustine

Obinutuzumab‐based induction and maintenance prolongs progression‐free survival in patients with previously untreated follicular lymphoma: primary results of the randomised phase 3 GALLIUM study

R Marcus - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Obinutuzumab

Minimal residual disease assessment in patients with follicular lymphoma treated with obinutuzumab or rituximab as first‐line induction immunochemotherapy in the phase 3 GALLIUM study

C Pott - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Obinutuzumab

Using a new patient feedback survey to explore experiences of living with sickle cell disease in the UK

S Chakravorty - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Whole exome sequencing in five patients with Sickle Cell Anaemia who had overt stroke before the age of three years

J Brewin - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Case report: severe bleeding phenotype due to undiagnosed α2 antiplasmin deficiency with novel gene mutation identified

A Zaidi - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Tranexamic acid

Reduced cortical thickness in patients with sickle cell disease and a high pain burden: baseline results from the Prevention of Morbidity in Sickle Cell Anaemia (POMS2b) trial

J Kawadler - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

The changing pattern of pulmonary complications reported to SHOT

P Bolton-Maggs - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Transfusion errors in transplantation

P Bolton-Maggs - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Allopurinol

2016 National audit of red cell use in adult haematology patients

M Karakantza - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Risk and impact of haemolytic transfusion reaction due to passive ABO antibodies as evidenced by serious hazards of transfusion data

C Milkins - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

IVIG

Sustained improvement over three years in the investigation and management of iron deficiency anaemia in a London Teaching Hospital

H Renshaw - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Epidemiology of massive transfusion at Barts and the Royal London Hospitals over a three year period (2012–2014)

L Green - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Age‐related changes in full blood counts – analysis of over 900,000 samples obtained from patients in primary care

R Phillips - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Patient perceptions on the symptomatic and economic burden of myeloproliferative neoplasms

C Harrison - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

The real world use of bosutinib in patients with chronic myeloid leukaemia

J Apperley - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bosutinib

A retrospective analysis of patients testing positive for the JAK2 V617F mutation: correlation between mutant allele burden and disease phenotype

MS Chapman - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Ruxolitinib in myelofibrosis: a multicentre experience from the East of England

J Russell - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Erythropoietin

Development of a mobile phone app to empower and support self‐monitoring in patients with myeloproliferative neoplasm and splanchnic vein thrombosis (MPN‐SVT)

L Pathirana - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Oral anticoagulant agent‐associated bleeding events reporting system (ORANGE) study

L Green - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Prothrombin complex

Copyright © 2026. QuantiNova All rights reserved